Matthew W. Foehr Insider Information
Matthew W. Foehr, has been our President and Chief Operating Officer since January 2015. Prior to that time, Mr. Foehr served as our Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior to joining our company in 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK’s $3.6 billion acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from February 2015 until its merger with Qualigen Therapeutics, Inc. in May 2020. Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his B.S. degree in biology from Santa Clara University.
What is Matthew W. Foehr's net worth?
The estimated net worth of Matthew W. Foehr is at least $15.03 million as of May 13th, 2022. Mr. Foehr owns 173,354 shares of Ligand Pharmaceuticals stock worth more than $15,034,992 as of May 16th. This net worth evaluation does not reflect any other investments that Mr. Foehr may own. Additionally, Mr. Foehr receives a salary of $909,000.00 as COO at Ligand Pharmaceuticals. Learn More about Matthew W. Foehr's net worth.
How old is Matthew W. Foehr?
Mr. Foehr is currently 49 years old. There are 4 older executives and no younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals is Mr. Charles S. Berkman J.D., Sr. VP, Gen. Counsel & Sec., who is 53 years old. Learn More on Matthew W. Foehr's age.
What is Matthew W. Foehr's salary?
As the COO of Ligand Pharmaceuticals Incorporated, Mr. Foehr earns $909,000.00 per year. The highest earning executive at Ligand Pharmaceuticals is Mr. John L. Higgins, CEO & Exec. Director, who commands a salary of $1,230,000.00 per year. Learn More on Matthew W. Foehr's salary.
How do I contact Matthew W. Foehr?
Has Matthew W. Foehr been buying or selling shares of Ligand Pharmaceuticals?
In the last ninety days, Matthew W. Foehr has bought $206,900.00 in shares of Ligand Pharmaceuticals stock. Most recently, on Friday, May 13th, Matthew W. Foehr bought 2,500 shares of Ligand Pharmaceuticals stock. The stock was acquired at an average cost of $82.76 per share, with a total value of $206,900.00. Following the completion of the transaction, the chief operating officer now directly owns 173,354 shares of the company's stock, valued at $14,346,777.04. Learn More on Matthew W. Foehr's trading history.
Who are Ligand Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Ligand Pharmaceuticals?
During the last year, Ligand Pharmaceuticals insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $206,900.00. During the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 23,908 shares worth more than $3,363,464.96. The most recent insider tranaction occured on May, 13th when COO Matthew W Foehr bought 2,500 shares worth more than $206,900.00. Insiders at Ligand Pharmaceuticals own 9.7 % of the company.
Learn More about insider trades at Ligand Pharmaceuticals. Information on this page was last updated on 5/13/2022.
Matthew W. Foehr Insider Trading History at Ligand Pharmaceuticals
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/13/2022 | Buy | 2,500 | $82.76 | $206,900.00 | 173,354 |  |
| 11/11/2021 | Sell | 11,160 | $163.02 | $1,819,303.20 | | |
| 8/4/2021 | Sell | 8,840 | $109.67 | $969,482.80 | 173,195 | |
| 2/4/2021 | Sell | 44,547 | $176.86 | $7,878,582.42 | 167,198 | |
| 8/24/2020 | Sell | 78 | $110.89 | $8,649.42 | 155,413 | |
| 8/21/2020 | Sell | 7,225 | $112.88 | $815,558.00 | 155,413 | |
| 2/27/2020 | Buy | 7,225 | $14.47 | $104,545.75 | 160,968 | |
| 2/27/2020 | Buy | 1,706 | $21.92 | $37,395.52 | 155,449 | |
| 2/27/2020 | Sell | 7,225 | $110.00 | $794,750.00 | 160,968 | |
| 2/15/2020 | Sell | 869 | $97.23 | $84,492.87 | 155,360 | |
| 2/15/2020 | Sell | 447 | $97.23 | $43,461.81 | 154,913 | |
| 2/15/2020 | Sell | 1,170 | $97.23 | $113,759.10 | 153,743 | |
| 2/14/2020 | Buy | 7,225 | $14.47 | $104,545.75 | 163,454 | |
| 2/14/2020 | Sell | 7,225 | $95.84 | $692,444.00 | 148,833 | |
| 2/13/2020 | Buy | 496 | $21.92 | $10,872.32 | 148,833 | |
| 2/13/2020 | Buy | 7,396 | $0.00 | $0.00 | 156,229 | |
| 10/1/2018 | Sell | 12,000 | $273.88 | $3,286,560.00 | 105,388 | |
| 9/4/2018 | Sell | 12,000 | $255.01 | $3,060,120.00 | 103,300 | |
| 5/10/2018 | Sell | 8,881 | $167.63 | $1,488,722.03 | 110,082 | |
| 2/23/2018 | Sell | 5,444 | $152.98 | $832,823.12 | 95,835 | |
| 8/9/2017 | Sell | 6,100 | $127.51 | $777,811.00 | 101,020 | |
| 5/12/2017 | Sell | 5,621 | $112.20 | $630,676.20 | 98,341 | |
| 3/2/2017 | Sell | 6,879 | $103.39 | $711,219.81 | 97,599 | |
| 3/17/2016 | Sell | 6,400 | $96.70 | $618,880.00 | 83,062 | |
| 6/26/2015 | Sell | 12,500 | $100.97 | $1,262,125.00 | | |
| 6/22/2015 | Sell | 23,046 | $96.45 | $2,222,786.70 | | |
| 6/28/2013 | Buy | 1,059 | $17.36 | $18,384.24 | | |
Ligand Pharmaceuticals Company Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Read More
Today's Range
Now:
$86.73
Volume
134,855 shs
Average Volume
163,104 shs
Market Capitalization
$1.46 billion
P/E Ratio
62.85
Dividend Yield
N/A
Beta
1.22
